Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NODAGA(KuE-pdz-JMV594)
- Development stage
- Preclinical
- Lead developer
- Université de Bourgogne
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-NODAGA(KuE-pdz-JMV594) is a heterobivalent radiopharmaceutical designed for positron emission tomography (PET) imaging of prostate cancer. It simultaneously targets two biomarkers overexpressed in prostate cancer: Prostate-Specific Membrane Antigen (PSMA) and Gastrin-Releasing Peptide Receptor (GRPR). The tracer is constructed using a pdz trifunctional platform based on a 3,6-dichlorotetrazine scaffold, which conjugates the PSMA-targeting urea-based inhibitor KuE (lysine-urea-glutamate) and the GRPR-targeting antagonist peptide JMV594 to a NODAGA chelator. Radiolabeled with gallium-68 ([68Ga]), this agent enables dual-receptor PET-CT imaging, offering potentially higher tumor uptake, longer residence time, and improved diagnostic sensitivity compared to monovalent tracers, particularly in heterogeneous tumors where PSMA and GRPR expression may vary.
- Other names
- [67Ga]Ga-NODAGA(KuE-pdz-JMV594)NODAGA(KuE-pdz-JMV594)
02
Targets
GRPR (Gastrin-releasing peptide receptor)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [68Ga]Ga-NODAGA(KuE-pdz-JMV594).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-NODAGA(KuE-pdz-JMV594).